Ther Adv Psychopharmacol. 2015 Apr;5(2):88-96. doi: 10.1177/2045125314566808.

Clozapine prescribing in the UK: views and experience of consultant psychiatrists.

Therapeutic advances in psychopharmacology

Tongeji E Tungaraza, Saeed Farooq

PMID: 26240748 PMCID: PMC4521444 DOI: 10.1177/2045125314566808

Abstract

OBJECTIVES: It has been repeatedly shown that clozapine is underutilized and there is delayed use of it in clinical practice.

METHOD: An online survey was sent to 2771 consultant psychiatrists registered with the Royal College of Psychiatrists in the UK. A total of 243 responded to this survey. The survey elicited their views and experiences in using clozapine as well as to identify what may be the underlying causes for its underutilization.

RESULTS: Over 75% acknowledged that they had good training in using clozapine and about 56% had clozapine-dedicated service. However, 40.5% preferred to use several other antipsychotics prior to considering clozapine. A third felt it was not safe to start clozapine in the community and 42% had less than five patients on clozapine. Eleven possible reasons for clozapine underutilization were identified including concerns about side effects, patients not wanting to have blood tests and lack of experience or knowledge. Knowledge deficiency in certain aspects of clozapine use were identified, e.g. a third of respondents did not know that the risk of agranulocytosis changes with time, 42.7% did not think that clozapine can reduce substance use, while 20% were not aware of its benefit in reducing suicidal risk.

CONCLUSIONS: Important areas of concern such as managing side effects and deficiency in evidence-based use of clozapine were identified. These can be targeted in training and professional development programme.

Keywords: antipsychotics; clozapine; treatment-resistant schizophrenia

References

1. J Clin Psychiatry. 2008 Feb;69(2):240-5 - PubMed
2. J Clin Psychiatry. 2000;61 Suppl 8:14-7; discussion 18-9 - PubMed
3. Arch Gen Psychiatry. 1988 Sep;45(9):865-7 - PubMed
4. Int Clin Psychopharmacol. 2011 Nov;26(6):311-5 - PubMed
5. Schizophr Bull. 1991;17(2):247-61 - PubMed
6. Arch Gen Psychiatry. 1988 Sep;45(9):789-96 - PubMed
7. Br J Psychiatry. 2011 Apr;198(4):247-9 - PubMed
8. J Psychiatry Neurosci. 2010 May;35(3):147-9 - PubMed
9. Am J Psychiatry. 1999 Jul;156(7):990-9 - PubMed
10. Schizophr Bull. 2002;28(1):31-42 - PubMed
11. Ann Pharmacother. 2008 Jun;42(6):852-60 - PubMed
12. Arch Gen Psychiatry. 2003 Jun;60(6):553-64 - PubMed
13. CNS Drugs. 2004;18(13):845-52 - PubMed
14. Acta Psychiatr Scand. 2014 Jul;130(1):16-24 - PubMed
15. J Psychopharmacol. 2010 Jul;24(7):965-71 - PubMed
16. Schizophr Bull. 2006 Oct;32(4):715-23 - PubMed
17. J Clin Psychiatry. 2003 Jan;64(1):30-4 - PubMed
18. Seizure. 2010 Mar;19(2):69-73 - PubMed
19. Int Clin Psychopharmacol. 2014 Mar;29(2):63-76 - PubMed
20. N Engl J Med. 1997 Sep 18;337(12):809-15 - PubMed
21. Schizophr Bull. 1998;24(3):381-90 - PubMed
22. Schizophr Bull. 2004;30(2):255-64 - PubMed
23. J Clin Psychiatry. 1999;60 Suppl 12:39-42 - PubMed
24. Br J Psychiatry. 1999 Dec;175:576-80 - PubMed
25. J Clin Psychiatry. 2013 Jun;74(6):603-13; quiz 613 - PubMed
26. Lancet. 1999 Nov 27;354(9193):1841-5 - PubMed
27. Curr Drug Saf. 2011 Jul;6(3):164-84 - PubMed
28. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD000059 - PubMed
29. J Psychiatr Pract. 2008 Nov;14(6):333-44 - PubMed
30. Br J Psychiatry. 2012 Dec;201(6):425-7 - PubMed
31. Am J Psychiatry. 2006 Apr;163(4):600-10 - PubMed
32. Curr Drug Saf. 2012 Feb;7(1):55-62 - PubMed
33. Acta Psychiatr Scand. 2014 Jul;130(1):30-9 - PubMed
34. Br J Psychiatry. 2012 Dec;201(6):481-5 - PubMed
35. J Psychopharmacol. 2012 Sep;26(9):1194-200 - PubMed
36. Can J Psychiatry. 2010 Oct;55(10):677-84 - PubMed
37. J Clin Psychiatry. 1998;59 Suppl 3:3-7 - PubMed

Publication Types

• Journal Article